Stifel analyst Chad Vanacore downgraded Omega Healthcare to Hold from Buy and maintained his $39 price target, citing valuation with the stock having risen 12% since the beginning of the year. The company’s restructuring is substantially complete and the timing of its investments is skewed to the back half of the year, Vanacore noted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.